Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1401929 | 1.00 | CYP19A1 (0.40) | CYP19A1NR3C1 | |
| SCHEMBL10529663 | 0.84 | CYP19A1 (0.38) | CYP19A1NR3C1 | |
| SCHEMBL10529661 | 0.84 | CYP19A1 (0.38) | CYP19A1NR3C1 | |
| SCHEMBL11639279 | 0.76 | CYP19A1 (0.43) | CYP19A1NR3C1 | |
| SCHEMBL8999955 | 0.76 | CYP19A1 (0.41) | CYP19A1NR3C1 | |
| SCHEMBL10942965 | 0.75 | CYP19A1 (0.44) | CYP19A1 | |
| SCHEMBL10942830 | 0.75 | NFKB1 (0.35) | CYP19A1 | |
| SCHEMBL9470387 | 0.74 | ESR1 (0.46) | CYP19A1NR3C1 | |
| SCHEMBL8999950 | 0.74 | CYP19A1 (0.70) | CYP19A1 | |
| SCHEMBL6437116 | 0.74 | CASP1 (0.51) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12594262-B2 | CAI nanoemulsions | FORWARDVUE PHARMA, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-20250387259-A1 | OCULAR IMPLANTS FOR CONTROLLED DRUG RELEASE | UNIV CALIFORNIA (US) | 2025-12-25 | — | — | US | disclosed |
| US-12447242-B2 | Hemostatic devices and methods of use | MEDTRONIC, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| EP-3452124-B1 | HEMOSTATIC DEVICES AND METHODS OF USE | MEDTRONIC INC (US) | 2025-10-08 | — | — | EP | disclosed |
| EP-3452123-B1 | HEMOSTATIC DEVICES AND METHODS OF USE | MEDTRONIC INC (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-3452126-B1 | HEMOSTATIC DEVICES AND METHODS OF USE | MEDTRONIC INC (US) | 2025-08-27 | — | — | EP | disclosed |
| US-20250262358-A1 | SURGICAL SYSTEM AND METHODS OF USE | MEDTRONIC INC (US) | 2025-08-21 | — | — | US | disclosed |
| EP-3452125-B1 | CUSTOMIZABLE ANCHORAGE DEVICES AND METHODS OF USE | MEDTRONIC INC (US) | 2025-07-16 | — | — | EP | disclosed |
| US-12168085-B2 | Surgical system and methods of use | MEDTRONIC, INC (US) | 2024-12-17 | — | — | US | disclosed |
| US-12168086-B2 | Hemostatic devices and methods of use | MEDTRONIC, INC (US) | 2024-12-17 | — | — | US | disclosed |
| US-5750745-A | STEROIDS | SCHERING CORPORATION (US) | 1998-05-12 | — | — | US | disclosed |
| US-4619921-A | Polyhalogeno-steroids | CIBA-GEIGY CORPORATION (US) | 1986-10-28 | — | — | US | disclosed |
| EP-0061416-B1 | PROCESS FOR THE PREPARATION OF DELTA 9(11)- AND DELTA 16-21-CHLORO-20-KETO STEROIDS OF THE PREGNANE AND D-HOMOPREGNANE SERIES AND THEIR USE AS INTERMEDIATES FOR THE SYNTHESIS OF HIGHLY EFFECTIVE CORTICOIDS | SCHERING AKTIENGESELLSCHAFT (DE) | 1985-11-13 | — | — | EP | disclosed |
| US-4310466-A | ANTIINFLAMMATORY STEROIDS | SYNTEX (U.S.A.) INC. (US) | 1982-01-12 | — | — | US | disclosed |
| US-4273770-A | CORTICOIDS, ANTIINFLAMMATORY AGENTS | SYNTEX (U.S.A.) INC. (US) | 1981-06-16 | — | — | US | disclosed |
| US-4263289-A | ANTIINFLAMMATORY STEROIDS | SYNTEX (U.S.A.) INC. (US) | 1981-04-21 | — | — | US | disclosed |
| EP-0004741-B1 | THIO ETIANIC ACID DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL USE | SYNTEX (U.S.A.) INC. (US) | 1981-01-28 | — | — | EP | disclosed |
| US-4188385-A | ANTIINFLAMMATORY STERIODS | SYNTEX (U.S.A.) INC. (US) | 1980-02-12 | — | — | US | disclosed |
| EP-0004741-A2 | Thio etianic acid derivatives, their preparation and pharmaceutical use | SYNTEX (U.S.A.) INC. (US) | 1979-10-17 | — | — | EP | disclosed |
| US-4088537-A | BIOTRANSFORMATION | THE UPJOHN COMPANY (US) | 1978-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12168086-B2 | Hemostatic devices and methods of use | PLAT, HABP2, F2 | CYP19A1 2624/4885NR3C1 4241/4885 |
| US-12594262-B2 | CAI nanoemulsions | KDR, FLT4, FLT1 | CYP19A1 2041/4885NR3C1 4041/4885 |
| US-12168085-B2 | Surgical system and methods of use | FGB, F2, COL14A1 | CYP19A1 1142/4885NR3C1 3249/4885 |
| US-12447242-B2 | Hemostatic devices and methods of use | HABP2, PLAT, F2 | CYP19A1 1877/4885NR3C1 4285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.